ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Zacks·1d ago
More News
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Zacks·1d ago
Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings
Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates.
Zacks·1d ago
ANI (ANIP) Upgraded to Strong Buy: Here's Why
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·2d ago
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
Zacks·2d ago
TMO to Report Q3 Earnings: Life Science Solutions Segment in Focus
Thermo Fisher's Q3 results on Oct. 22 are set to spotlight gains from new launches and acquisitions across key growth segments.
Zacks·2d ago
Will Robust Cardiovascular Performance Fuel BSX's Q3 Earnings?
Boston Scientific's strong cardiovascular and MedSurg momentum, powered by innovations like WATCHMAN FLX Pro and AGENT DCB, could drive solid Q3 results.
Zacks·2d ago
Why ANI (ANIP) Could Beat Earnings Estimates Again
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·3d ago
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
Zacks·3d ago
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.